These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 16118767

  • 1. P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments.
    Ejsing TB, Pedersen AD, Linnet K.
    Hum Psychopharmacol; 2005 Oct; 20(7):493-500. PubMed ID: 16118767
    [Abstract] [Full Text] [Related]

  • 2. Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice.
    Kirschbaum KM, Henken S, Hiemke C, Schmitt U.
    Behav Brain Res; 2008 Apr 09; 188(2):298-303. PubMed ID: 18164477
    [Abstract] [Full Text] [Related]

  • 3. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
    Uchida Y, Ohtsuki S, Kamiie J, Terasaki T.
    J Pharmacol Exp Ther; 2011 Nov 09; 339(2):579-88. PubMed ID: 21828264
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.
    Zhou L, Schmidt K, Nelson FR, Zelesky V, Troutman MD, Feng B.
    Drug Metab Dispos; 2009 May 09; 37(5):946-55. PubMed ID: 19225039
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution.
    Shaik N, Giri N, Pan G, Elmquist WF.
    Drug Metab Dispos; 2007 Nov 09; 35(11):2076-85. PubMed ID: 17709369
    [Abstract] [Full Text] [Related]

  • 11. The role of P-glycoprotein in intestinal transport versus the BBB transport of tetraphenylphosphonium.
    Swed A, Eyal S, Madar I, Zohar-Kontante H, Weiss L, Hoffman A.
    Mol Pharm; 2009 Nov 09; 6(6):1883-90. PubMed ID: 19722701
    [Abstract] [Full Text] [Related]

  • 12. The Differential Binding of Antipsychotic Drugs to the ABC Transporter P-Glycoprotein Predicts Cannabinoid-Antipsychotic Drug Interactions.
    Brzozowska NI, de Tonnerre EJ, Li KM, Wang XS, Boucher AA, Callaghan PD, Kuligowski M, Wong A, Arnold JC.
    Neuropsychopharmacology; 2017 Oct 09; 42(11):2222-2231. PubMed ID: 28272498
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y.
    J Pharmacol Exp Ther; 2010 Jun 09; 333(3):788-96. PubMed ID: 20304939
    [Abstract] [Full Text] [Related]

  • 17. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
    Durmus S, Xu N, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2013 Oct 09; 76():9-16. PubMed ID: 23827160
    [Abstract] [Full Text] [Related]

  • 18. Risperidone and paliperidone inhibit p-glycoprotein activity in vitro.
    Zhu HJ, Wang JS, Markowitz JS, Donovan JL, Gibson BB, DeVane CL.
    Neuropsychopharmacology; 2007 Apr 09; 32(4):757-64. PubMed ID: 16936711
    [Abstract] [Full Text] [Related]

  • 19. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H, Kusuhara H, Fujita T, Ushiki J, Fuse E, Sugiyama Y.
    J Pharmacol Exp Ther; 2011 Dec 09; 339(3):935-44. PubMed ID: 21934030
    [Abstract] [Full Text] [Related]

  • 20. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
    Graber-Maier A, Gutmann H, Drewe J.
    Mol Pharm; 2010 Oct 04; 7(5):1618-28. PubMed ID: 20701289
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.